for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Reneo Pharmaceuticals Inc

RPHM.OQ

Latest Trade

7.80USD

Change

0.00(-0.00%)

Volume

4,540

Today's Range

7.73

 - 

8.05

52 Week Range

6.12

 - 

16.83

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.80
Open
8.05
Volume
4,540
3M AVG Volume
1.74
Today's High
8.05
Today's Low
7.73
52 Week High
16.83
52 Week Low
6.12
Shares Out (MIL)
24.41
Market Cap (MIL)
197.68
Forward P/E
-2.54
Dividend (Yield %)
--

Next Event

Reneo Pharmaceuticals Inc at SVB Leerink Neuromuscular, Rare Diseases & Genetic Medicines Event (Virtual)

Latest Developments

More

Reneo Pharmaceuticals Q1 Loss Per Share $3.48

Reneo Pharmaceuticals Announces Pricing Of Initial Public Offering

Reneo Pharmaceuticals Inc Sees IPO Of 6.3 Mln Shares Of Common Stock Priced To Be Between $15 And $17 Per Share

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Reneo Pharmaceuticals Inc

Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the developing therapies for patients with rare genetic mitochondrial diseases. The Company is engaged in developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the source of energy for cellular processes. REN001 is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist that has been shown to transcription of genes involved in mitochondrial function and fatty acid oxidation (FAO). The Company is developing REN001 in the three rare genetic diseases that present with myopathy and have unmet medical need: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disease type V (McArdle disease). The Company has completed Phase I b clinical trial in patients with PMM to REN001. It is conducting open-label Phase I b clinical trials of REN001 with LC-FAOD and with McArdle disease.

Industry

Business Services

Contact Info

18575 Jamboree Road, Suite 275-S

IRVINE, CA

92612

United States

+1.858.2830280

https://reneopharma.com/

Executive Leadership

Mike Grey

Executive Chairman of the Board, Founder

Gregory J. Flesher

President, Chief Executive Officer, Director

Niall O'donnell

Co-Founder, Director

Vinny Jindal

Chief Financial Officer

Lynn Purkins

Vice President of Clinical Operations

Key Stats

1.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2021(E)

0.0K
EPS (USD)

2021(E)

-3.183
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.17
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up